Clonidine Patch for Tourette Syndrome With Attention-Deficit/Hyperactivity Disorder

Area of Science:

• Neurology
• Pediatrics
• Pharmacology

Background:

• Tourette syndrome (TS) frequently co-occurs with attention-deficit/hyperactivity disorder (ADHD).
• Managing comorbid TS and ADHD presents unique clinical challenges.
• Non-stimulant medications are often considered for ADHD in TS patients.

Purpose of the Study:

• To evaluate the efficacy and safety of the clonidine adhesive patch in pediatric patients with TS and comorbid ADHD.
• To determine optimal dosing for tic symptom control.

Main Methods:

• A randomized, placebo-controlled trial involving children and adolescents diagnosed with TS and ADHD.
• Patients were assigned to clonidine adhesive patch doses of 1.0 mg/week, 1.5 mg/week, 2.0 mg/week, or placebo.
• Tic severity was assessed using the Yale Global Tic Severity Scale, and ADHD symptoms via the Swanson, Nolan, and Pelham Rating Scale (SNAP-IV).

Main Results:

• Clonidine adhesive patch significantly improved tic disorder (TD) effective rates at week 8 compared to placebo (85.7%, 81.5%, 86.1% vs. 20.7%).
• All clonidine groups showed significant improvement in SNAP-IV scores from baseline, though not statistically different from placebo at week 8.
• Nine adverse reactions were reported, all mild and self-resolving.

Conclusions:

• The clonidine adhesive patch is a safe and effective option for reducing tic symptoms in TS patients with comorbid ADHD.
• The treatment may offer potential benefits for managing ADHD symptoms in this population.